Abstract
The American Society of Clinical Oncology (ASCO) Annual Meeting is one of the most highly anticipated events in oncology. This year, it took place from May 29 to June 2 in Chicago, with over 35,000 medical professionals attending. As a hematology advanced practitioner (AP) specialist with over two decades of experience, I look forward to this meeting for its presentations of practice-changing advancements in oncology.
References
Catamero, D., Richards, T., & Faiman, B. (2022). A focus on CAR T-cell therapy and bispecific antibodies in multiple myeloma. JADPRO, 13(Suppl 4), 31–43. https://doi.org/10.6004/jadpro.2022.13.5.13
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., Reece, D., Niu, T., Mylin, A. K., Hansen, C. T., Teipel, R., Besemer, B., Dimopoulos, M. A., Zamagni, E., Yoshihara, S., Kim, K.,…MajesTEC-3 Trial Investigators (2026). Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. The New England Journal of Medicine, 394(8), 739–752. https://doi.org/10.1056/NEJMoa2514663
Granat, L., Carraway, H., and Molina, J. (2026). H.O.P.E. (Hematology/Oncology Practical Education): A pilot curriculum. Journal of Clinical Oncology, 44(16 suppl), e21007(2026). https://doi.org/10.1200/JCO.2026.44.16_suppl.e21007
Mina, R., Touzeau, C., Hungria, V., Landgren, C. O., Bhutani, D., Chen, W., Kumar, S., Chaulagain, C. P., Dimopoulos, M. A., Bahlis, N. J., Maral, S., van de Donk, N. W. C. J., Saja, K., Teipel, R., Ando, M., Wang, D., Wroblewski, S., Vanquickelberghe, V., Shah, P.,...Quach, H. (2026). MajesTEC-9: A phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone (PVd/Kd) in patients (pts) with relapsed refractory multiple myeloma (RRMM). Journal of Clinical Oncology, 44(16_suppl), 7507. https://doi.org/10.1200/JCO.2026.44.16_suppl.7507
O’Reilly, E. M., Wainberg, Z. A., Hendifar, A. E., Borad, M. J., Pietrantonio, F., Pant, S., Hammel, P., Cremolini, C., Manji, G. A., Oberstein, P. E., Garrido-Laguna, I., Springfeld, C., Azad, N. S., Ueno, M., Chui, S. Y., Zhang, Y., Patel, H., Lee, Y., Salman, Z., Wolpin, B. M.,…RASolute 302 Trial Investigators (2026). Daraxonrasib or chemotherapy in previously treated metastatic pancreatic cancer. The New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2605555
Ramasamy, K., Vij, R., Kuter, D., Cella, D., Durie, B. G. M., Abonour, R., Rifkin, R. M., Ailawadhi, S., Lee, H. C., Cowan, A. J., Ho, C., Dhanasiri, S., Fish, S., Yu, E., Dhamane, A. D., Fang, J., Marshall, T. S., Samuel, A., Liu, L., Katz, J.,…Jagannath, S. (2025). Real-world treatment patterns and clinical outcomes in patients with multiple myeloma previously treated with lenalidomide and an anti-CD38 monoclonal antibody. Clinical Lymphoma, Myeloma & Leukemia, 25(5), 337–348.e2. https://doi.org/10.1016/j.clml.2024.12.002
